Takeda Pharmaceutical Company Limited (FRA: TKD)

Market Cap	40.73B
Revenue (ttm)	28.45B
Net Income (ttm)	1.81B
Shares Out	n/a
EPS (ttm)	1.14
PE Ratio	22.44
Forward PE	n/a
Dividend	98.61 (401.16%)
Ex-Dividend Date	Mar 28, 2025

Volume	180
Average Volume	367
Open	25.52
Previous Close	24.97
Day's Range	25.49 - 25.52
52-Week Range	23.37 - 27.51
Beta	n/a
RSI	55.56
Earnings Date	Jan 30, 2025

About FRA: TKD

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, A...

• Industry: Pharmaceutical Preparations
• Founded: 1781
• Employees: 49,281
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: TKD

Financial Performance

In 2023, TKD's revenue was 4.26 trillion, an increase of 5.87% compared to the previous year's 4.03 trillion. Earnings were 144.07 billion, a decrease of -54.56%.

Financial numbers in JPY